Levosimendan Protects against Doxorubicin-Induced Cardiotoxicity by Regulating the PTENAkt Pathway

Abstract EN

Background and Aims.

Myocyte apoptosis plays a critical role in the development of doxorubicin- (DOX-) induced cardiotoxicity.

In addition to its cardiotonic effect, laboratory evidence indicates that levosimendan can inhibit apoptosis, but its role in DOX-induced cardiac injury remains unclear.

Therefore, the present study is aimed at exploring whether levosimendan could attenuate DOX-induced cardiotoxicity.

Methods.

Levosimendan (1 mg/kg) was administered to mice through oral gavage once daily for 4 weeks, and the mice were also subjected to an intraperitoneal injection of DOX (5 mg/kg) or saline, once a week for 4 weeks, to create a chronic model of DOX-induced cardiotoxicity.

A morphological examination and biochemical analysis were used to evaluate the effects of levosimendan.

H9C2 cells were used to verify the protective role of levosimendan in vitro.

And an Akt inhibitor was utilized to verify the cardioprotection of levosimendan.

Results.

Levosimendan reduced the cardiac dysfunction and attenuated the myocardial apoptosis induced by DOX in vivo and in vitro.

Levosimendan also inhibited the activation of phosphatase and tensin homolog (PTEN) and upregulated P-Akt expression both in vivo and in vitro.

And inhibition of Akt abolished the cardioprotection of levosimendan in vitro.

Conclusion.

Levosimendan may protect against DOX-induced cardiotoxicity via modulation of the PTEN/Akt signaling pathway.